Hyponatremia in cancer patients: Time for a new approach
详细信息 查看全文
- 作者：Rossana Berardia ; r.berardi@univpm.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Silvia Rinaldia ; Miriam Caramantia ; Christian Grohè ; b ; Matteo Santonia ; Francesca Morgesea ; Mariangela Torniaia ; Agnese Savinia ; Ilaria Fiordolivaa ; Stefano Cascinua ; 1
- 关键词：Antidiuretic hormone ; Vasopressin ; Cancer ; Hyponatremia ; SIADH ; Sodium
- 刊名：Critical Reviews in Oncology and Hematology
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：102
- 期：Complete
- 页码：15-25
- 全文大小：829 K
文摘
- •
Hyponatremia is relevant in cancer patients because it may have a negative impact on outcome, on quality of life and on length of hospitalization.
- •
There are evidences that the inappropriate antidiuretic hormone syndrome (SIADH) is the most common cause of hyponatremia in cancer patients.
- •
An early detection, monitoring and prompt management is needed to improve the patient’s outcome and several options are available.
- •
Several studies have demonstrated the efficacy and good tolerability of Tolvaptan for the treatment of SIADH-related hyponatremia even in cancer patients.